title: In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine.
abstract: Previously, a panel of mouse monoclonal antibodies (mAbs) to several tumor-associated antigens was chemically crosslinked to an IgG1 anti-human transferrin receptor antibody, 454A12. We called this new class of bispecific antibodies (BmAbs) "antigen forks" and showed that these antigen forks inhibited but did not completely prevent tumor cell growth. We speculated that the conjugates acted by heterologously crosslinking two antigens in a manner that interfered with the functions of one or both. The most effective BmAbs all shared one specificity for the human transferrin receptor. A monoclonal antibody to this receptor has been shown by others to reduce tumor cell growth when used with the iron chelator deferoxamine. When we combined our antigen forks with deferoxamine, two of five BmAbs synergized with deferoxamine to arrest tumor cell count at or below input levels. The most effective BmAbs were 317G5/454A12 (3/4) and 520C9/454A12 (5/4). mAb 317G5 recognizes a 42-kDa tumor-associated glycoprotein, and mAb 520C9 recognizes the c-erbB-2 protooncogene product. BmAb 3/4 was most effective against colorectal cancer cell line HT-29, and BmAb 5/4 was most effective against breast cancer cell line SK-BR-3. When deferoxamine and BmAb were replaced by fresh medium after a 6- or 7-day treatment period, no regrowth of tumor cells was observed during the next 4 days, although regrowth was seen if either deferoxamine or BmAb was used alone. Our results show that BmAbs with specificities for transferrin receptor and certain tumor-associated antigens effectively inhibit tumor growth in vitro. When used in combination with deferoxamine, such BmAbs may have therapeutic potential for the treatment of cancer.
authors.affiliation: Department of Immunotherapeutics, Chiron Corporation, Emeryville, California 94608, USA.
authors.forename: S T
authors.initials: ST
authors.lastname: Hsieh-Ma
authors.forename: T
authors.initials: T
authors.lastname: Shi
authors.forename: J
authors.initials: J
authors.lastname: Reeder
authors.forename: D B
authors.initials: DB
authors.lastname: Ring
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D003676:Deferoxamine / Q000737:chemistry / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000276:immunology / Q000494:pharmacology*; D019073:HT29 Cells; D006801:Humans; D051379:Mice; D011990:Receptors, Transferrin / Q000276:immunology*; D017186:Titrimetry; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D018033:Antibodies, Bispecific; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D011990:Receptors, Transferrin; D003676:Deferoxamine